A meta-analysis of dizziness as an adverse reaction in novel endocrine therapy for advanced prostate cancer.

Key Points

• This analysis aims to evaluate the risk of dizziness associated with novel endocrine therapy in advanced prostate cancer patients.
• Conducted a meta-analysis of clinical data regarding dizziness as an adverse reaction to novel endocrine therapies.
• Subgroup analyses were performed based on different androgen receptor pathway inhibitors (ARPIs) including abiraterone, enzalutamide, and others.
• Statistical significance was assessed using appropriate metrics (p-values).
• Novel endocrine therapy with ARPIs increases the risk of all-grade dizziness in prostate cancer patients (not statistically significant for severe dizziness).
• Subgroup analyses did not indicate significant differences in dizziness risk between ARPI types (p = 0.2026).
• Overall risk of severe dizziness remains statistically non-significant (p = 0.8165).